AAAAAA
Results:
1-11
|
Results: 11
Authors:
Saves, M
Morlat, P
Chene, G
Peuchant, E
Pellegrin, I
Bonnet, F
Bernard, N
Lacoste, D
Salamon, R
Beylot, J
Citation: M. Saves et al., Prognostic value of plasma markers of immune activation in patients with advanced HIV disease treated by combination antiretroviral therapy, CLIN IMMUNO, 99(3), 2001, pp. 347-352
Authors:
Saves, M
Mercie, P
Chene, G
Citation: M. Saves et al., Lipodystrophic syndrome and antiretroviral treatments in HIV-infected patients, M S-MED SCI, 17(8-9), 2001, pp. 886-892
Authors:
Bonnet, F
Saves, M
Droz, C
Peuchant, E
Chene, G
Beylot, J
Morlat, P
Citation: F. Bonnet et al., Increase of lipid plasma concentrations under protease inhibitor-containing regimens are not related to modifications of the tumour necrosis factor system, AIDS, 15(7), 2001, pp. 940-941
Authors:
Jouan, M
Saves, M
Tubiana, R
Carcelain, G
Cassoux, N
Aubron-Olivier, C
Fillet, AM
Nciri, M
Senechal, B
Chene, G
Tural, C
Lasry, S
Autran, B
Katlama, C
Citation: M. Jouan et al., Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy, AIDS, 15(1), 2001, pp. 23-31
Authors:
Binquet, C
Chene, G
Jacqmin-Gadda, H
Journot, V
Saves, M
Lacoste, D
Dabis, F
Citation: C. Binquet et al., Modeling changes in CD4-positive T-lymphocyte counts after the start of highly active antiretroviral therapy and the relation with risk of opportunistic infections - The Aquitaine Cohort, 1996-1997, AM J EPIDEM, 153(4), 2001, pp. 386-393
Authors:
Bonnet, F
Saves, M
Droz, C
Peuchant, E
Chene, G
Beylot, J
Morlat, P
Citation: F. Bonnet et al., Increase of atherogenic plasma profile in HIV-infected patients treated with protease inhibitor-containing regimens, J ACQ IMM D, 25(2), 2000, pp. 199-200
Authors:
Saves, M
Chene, G
Suissa, S
Citation: M. Saves et al., Lipodystrophy and nucleoside analogue therapy in HIV-infected patients: Important question, few valid answers, J ACQ IMM D, 25(1), 2000, pp. 96-97
Authors:
Saves, M
Raffi, F
Clevenbergh, P
Marchou, B
Waldner-Combernoux, A
Morlat, P
Le Moing, V
Riviere, C
Chene, G
Leport, C
Citation: M. Saves et al., Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients, ANTIM AG CH, 44(12), 2000, pp. 3451-3455
Authors:
Chene, G
Saves, M
Salmi, LR
Citation: G. Chene et al., In clinical, trials, should we be blinded or masked? A proposal for becoming aware of the meaning behind words and concepts, CAN J PUBL, 91(2), 2000, pp. 158-158
Authors:
Saves, M
Vandentorren, S
Daucourt, V
Marimoutou, C
Dupon, M
Couzigou, P
Bernard, N
Mercie, P
Dabis, F
Citation: M. Saves et al., Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations Aquitaine Cohort, France, 1996-1998, AIDS, 13(17), 1999, pp. F115-F121
Authors:
Saves, M
Morlat, P
Chene, G
Domon, B
Peuchant, E
Citation: M. Saves et al., Sex differences in HIV-1 viral load and TNF-alpha plasmatic level?, AIDS, 13(11), 1999, pp. 1414-1415
Risultati:
1-11
|